The ongoing quest for biomarkers in Ankylosing Spondylitis (Q38607774)

4 September 2017

title

The ongoing quest for biomarkers in Ankylosing Spondylitis (English)

1 reference

4 September 2017

0 references

Abhijeet Danve

1

1 reference

4 September 2017

James O'Dell

series ordinal

2

1 reference

4 September 2017

publication date

15 October 2015

1 reference

International Journal of Rheumatic Diseases

4 September 2017

published in

1 reference

4 September 2017

volume

18

1 reference

4 September 2017

issue

8

1 reference

4 September 2017

page(s)

826-834

1 reference

Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Genetics of spondyloarthritis--beyond the MHC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

ANKH variants associated with ankylosing spondylitis: gender differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

A novel gene variation of TNFalpha associated with ankylosing spondylitis: a reconfirmed study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

The biochemistry and immunology of non-canonical forms of HLA-B27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

HLA-B27 misfolding and spondyloarthropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Time for a gut check: evidence for the hypothesis that HLA-B27 predisposes to ankylosing spondylitis by altering the microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey, 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Spondyloarthropathies in eastern Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Progress in the genetics of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Endoplasmic reticulum aminopeptidase 1 (ERAP1) exhibits functionally significant interaction with HLA-B27 and relates to subtype specificity in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Is there a higher genetic load of susceptibility loci in familial ankylosing spondylitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Associations between ERAP1 polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Molecular regulation of vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Occurrence, biochemical profile of vascular endothelial growth factor (VEGF) isoforms and their functions in endochondral ossification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Vascular endothelial growth factor (VEGF) in ankylosing spondylitis--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Influence of VEGF gene polymorphisms on the severity of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Regulation of bone mass by Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Update on Wnt signaling in bone cell biology and bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

New bone formation in axial spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Bone and cartilage turnover markers, bone mineral density, and radiographic damage in men with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Elevated serum anti-flagellin antibodies implicate subclinical bowel inflammation in ankylosing spondylitis: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Biomarkers of Bone Metabolism in Ankylosing Spondylitis in Relation to Osteoproliferation and Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Cartilage biomarkers in ankylosing spondylitis: Relationship to clinical variables and treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

Calprotectin in ankylosing spondylitis – frequently elevated in feces, but normal in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12779

21 January 2018

Identifiers

DOI

10.1111/1756-185X.12779

1 reference

4 September 2017

1 reference